Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study

CompletedOBSERVATIONAL

Enrollment

3,055

Participants

Timeline

Start Date

May 11, 2016

Primary Completion Date

February 21, 2019

Study Completion Date

September 24, 2019

Conditions

Stroke

Interventions

DRUG

Rivaroxaban (Xarelto, BAY 59-7939)

Decision regarding dose and duration of treatment made at the discretion of the attending investigator.

Trial Locations (1)

Hangzhou